regardless of promising clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing considerable resistance from managed care entities. Such organizations are typically building obstacles to coverage, such as high cost criteria and prior authorization that restrict consumer access. Ma